Drug firm Shilpa Medicare on Monday said it has received five observations from the US health regulator for its Raichur facility after the completion of an inspection.
"We have completed USFDA (United States Food and Drug Administration) audit at our API (active pharmaceutical ingredient) site, Raichur between July 22-26, 2019," Shilpa Medicare said in a filing to the BSE.
"We have received Form 483 with five observations, with no repeat observations and any data integrity observations. The observations are mostly procedural in nature," the company added.
As per the USFDA, observations are made in Form 483 when investigators feel that conditions or practises in the facility are such that products may become adulterated or render injuries to health.
The FDA Form 483 notifies the company's management of objectionable conditions.
Shares of Shilpa Medicare were trading 0.57 per cent higher at Rs 352 apiece on BSE.
Disclaimer: No Business Standard Journalist was involved in creation of this content
